From Lab Discovery to Global Impact: How Nova Medical Testing Inc. is Advancing Metabolomics in Alberta and Beyond

 

In the world of life sciences, timing is everything. While genomics can help predict what might happen in the body, metabolomics reveals what has already happened and provides a powerful perspective that is becoming increasingly important as researchers and companies seek more precise and actionable insights.

Nova Medical Testing Inc. is helping bring that perspective into sharper focus. From its origins at the University of Alberta to a growing international client base, the company has emerged as a key player in advancing metabolomics. What began as a university-based innovation has evolved into a growing Alberta company that is creating high-value jobs, attracting customers from around the world, and demonstrating how scientific discovery can be successfully translated into commercial impact.

A Platform Built on Precision

Founded in 2017 as a spinout from the University of Alberta, Nova Medical Testing Inc. is grounded in decades of scientific expertise. At the core of its innovation is a breakthrough developed by Dr. Liang Li: a Chemical Isotope Labelling (CIL) method that dramatically enhances the depth and sensitivity of metabolomics analysis.

“Metabolomics is essentially a real-time biological snapshot, and our CIL technology addresses the fundamental challenge of how to extract as much meaningful, high-quality data as possible from complex biological samples, without compromising cost or accuracy,” says Inderbeer Singh, Nova Medical Testing Inc.’s Operations Lead.

From this foundation, the company has developed a suite of proprietary platforms and services. Its flagship HP-CIL metabolomics platform enables high-performance untargeted analysis, while complementary offerings such as lipidomics services and the newer FOCUS targeted assays, expand its capabilities across specific metabolite classes.

Together, these platforms are not only advancing scientific understanding but also creating commercial opportunities across multiple sectors, including life sciences, agriculture, pharmaceuticals, biotechnology, and precision health. By serving a diverse customer base, Nova Medical Testing Inc. has built a business model that extends well beyond traditional academic research markets.

The Role of Early Support

Nova Medical Testing Inc.’s growth story is closely tied to the support it received in its early stages. While the company has built a strong and sustainable business model, its leadership is clear that early investment played a critical role in accelerating development.

Genome Alberta’s impact, particularly through the Bioinformatics Work Placement Program, has been especially meaningful. This talent placement program matches highly specialized graduates with companies and enabled Nova Medical Testing Inc. to build its software infrastructure at a crucial stage in its evolution. That infrastructure now underpins key areas of the company’s innovation pipeline, including biomarker discovery tools and precision health applications. More broadly, non-dilutive funding has allowed Nova Medical Testing Inc. to invest in areas that would have been difficult, if not impossible, through revenue alone.

“The support we received was instrumental in building our software infrastructure. Without those supports, we would be significantly further behind in our development trajectory” says Inderbeer. “Reaching the current stage without early funding would have been possible, but it would have set us back significantly.”

For emerging technology companies, early-stage funding often provides more than financial support. It creates the capacity to hire talent, develop new capabilities, and pursue market opportunities that might otherwise remain out of reach. In Nova Medical Testing Inc.’s case, those investments helped accelerate the company’s transition from research-driven innovation to commercial growth.

From Research to Revenue

Nova Medical Testing Inc. stands out for its ability to translate research into revenue early in its lifecycle. Its core analytical services, commercially active since 2017, have created a strong foundation for sustainable growth. More recent innovations, including the FOCUS platform, are already contributing to expanding revenue streams as they continue to be refined and scaled. Today, the company is firmly in the growth stage, employing 23 full-time staff based in Edmonton and serving clients across Canada, the United States, and Europe.

The company’s client base is both diverse and evolving. Academic institutions continue to play a central role, reflecting the company’s research roots. At the same time, Nova Medical Testing Inc. is expanding its presence in industry and applied research, particularly in the United States, where the demand for advanced metabolomics is rapidly growing.

This steady growth has been achieved without traditional venture capital investment. Instead, Nova Medical Testing Inc. has focused on raising non-dilutive funding from organizations such as the National Research Council, Alberta Innovates, and BioTalent Canada. This approach has allowed the company to scale in a deliberate and strategic way, reinvesting in its technology while maintaining independence and focus. As the company expands into larger international markets, particularly the United States, it is also contributing to Alberta’s export economy by bringing external revenue, investment, and business opportunities back to the province.

Building an Ecosystem, Not Just a Company

Nova Medical Testing Inc.’s impact extends beyond its own operations. Through collaborations with academic researchers and international partners, the company is helping to strengthen Alberta’s broader life sciences ecosystem.

One example is its internally developed biomarker discovery software, which has been applied through collaborations with prominent University of Alberta researchers across a range of research projects. This work combines Nova Medical Testing Inc.’s analytical capabilities with advanced research data to support new tools for scientific discovery and downstream applications. These types of partnerships are helping to generate new knowledge while also creating pathways for future innovation.

The company also works closely with The Metabolomics Innovation Centre (TMIC), leveraging shared infrastructure to deliver high-quality analytical services to clients around the world. This relationship enhances both capacity and capability, allowing Nova Medical Testing Inc. to operate at a level that would be difficult to achieve independently.

This collaborative approach reflects a broader shift in biotechnology, whereby innovation increasingly occurs at the intersection of academia, industry, and enabling organizations. Companies that are able to navigate and contribute to this ecosystem are better positioned to scale their impact.

The benefits extend beyond any single company. Strong partnerships help retain expertise in Alberta, create opportunities for highly qualified talent, and build the infrastructure needed to support future commercialization successes across the province’s growing life sciences sector.

Elevating Metabolomics in Alberta

Beyond its own commercial success, Nova Medical Testing Inc. is playing a key role in elevating metabolomics within Alberta’s life sciences landscape. Compared to genomics, metabolomics has historically received less attention and funding. But that is beginning to change, thanks in part to companies like Nova Medical Testing Inc. that are demonstrating its real-world value.

By providing advanced analytical capabilities and expanding the range of applications for metabolomics, the company is helping to reposition the field as a critical component of modern biological research and precision health. In doing so, it is also helping establish Alberta as a destination for specialized expertise in a rapidly growing area of life sciences.

This shift has implications not only for science, but for economic development as well, and as metabolomics gains traction, it opens new opportunities for innovation, commercialization, and collaboration, both within Alberta and globally.

From Alberta Innovation to Global Opportunity

With a proven platform, growing revenue, and expanding market reach, Nova Medical Testing Inc. is well-positioned for its next phase of growth.

The company is actively scaling its presence in the United States, deepening its industry partnerships, and advancing new applications in precision health. While at the same time, it continues to refine its technologies and expand its service offering, ensuring it remains at the forefront of metabolomics innovation.

Its journey underscores a broader truth about innovation in that breakthrough science is only part of the equation. Translating that science into real-world impact requires the right combination of funding, collaboration, and strategic vision.

Nova Medical Testing Inc.’s growth demonstrates the long-term value of investing in research commercialization. What began as a university innovation has become a revenue-generating Alberta company with an international customer base, creating skilled jobs, attracting global business, and contributing to the continued growth of the province’s life sciences economy.

For Alberta, stories like Nova Medical Testing Inc.’s illustrate how strategic support for emerging technologies can create lasting economic returns while positioning the province as a competitive player in global health and biotechnology markets.

Read more about Genome Alberta’s programs to support commercialization:

• National Genomic Applications Partnership Program (N-GAPP)
• Regional Genomic Applications Partnership Program (R-GAPP)

Read the articles in this series:

• From Discovery to Market I: Luminous BioSolutions
• From Discovery to Market II: Nova Medical Testing Inc.
• From Discovery to Market III: Metabolomix (coming August 2026)
• From Discovery to Market IV: Rapid Infection Diagnostics Inc. (coming August 2026)